Skip to main content
Fig. 5 | The Journal of Headache and Pain

Fig. 5

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 5

Change in monthly days of acute medication use in participants aged ≥60 years and overall population. LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. Data shown are the LSM changes from baseline in the monthly average number of days of acute headache medication use during 12 weeks of double-blind treatment. aP < 0.001 vs placebo. bP ≤ 0.0001 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us